Contraceptive Technology Update – June 1, 2018
June 1, 2018
View Issues
-
Training Can Help Integrate LARC Options Into Contraceptive Care
Research from the Bixby Center for Global Reproductive Health at the University of California, San Francisco, and Planned Parenthood Federation of America indicates that a four-hour training intervention can significantly affect the likelihood that healthcare providers will integrate long-acting reversible contraceptives into their clinical care.
-
Check Access to Prescription-Only, OTC Emergency Contraception
According to a new national survey, less than 10% of pharmacies have the ability to fill a prescription immediately for ulipristal acetate, the prescription-only form of emergency contraception (EC).
-
Report: Abortion Safe, but Access to the Procedure May Be Limited
A new report has determined that while abortion in the United States is safe, the quality of abortion care depends on where a woman lives.
-
Study Examines Disparity of Trichomoniasis
Results of a new analysis indicate that trichomoniasis disproportionately affects the black community. Data indicate that while the prevalence of Trichomonas vaginalis infection was 0.03% and 0.8% among males and females of other races/ethnicities, the prevalence was significantly higher among black males and females at 4.2% and 8.9%, respectively.
-
Research Examines Male Contraception Option
Researchers at the University of Washington and Harbor-University of California, Los Angeles Medical Center are evaluating the use of a daily contraceptive pill containing dimethandrolone undecanoate for men.
-
Beyond Efficacy: Applying a Reproductive Justice Framework to Contraceptive Counseling for Young People
A counseling approach that supports bodily autonomy, dignity, and agency of persons works toward ensuring reproductive justice.
-
Clinical Challenge: PrEP Is Not Reaching Most of the People Who Are at Risk
CDC leads efforts to build PrEP awareness and expand availability.
-
Researchers Examine Possible Capsule Option for HIV Drugs
Early research is focusing on a capsule that can deliver a week’s worth of HIV drugs in a single dose. If confirmed in advanced research, such an option could allow patients to stay compliant with the dosing regimen required to fight the virus successfully.